Subgroup and recurrence-free survival analysis. (A) Subgroup analysis of the patients with negative/low slope (n = 138): The central part reproduces an inset of the logistic regression curve for patient-specific estimates of the individual BCR-ABL1^IS slope during the 12-month dose reduction period. Patients are categorized according to their prior BCR-ABL1^IS level as either MR3 (rhombi) or MR4 (filled circles). The upper and lower panels depict the slope distributions of patients with and without molecular recurrence, respectively, stratified for the molecular response level before dose reduction (ie, MR3: dark shaded; MR4: light shaded). Small ticks indicate the estimates of the individual BCR-ABL1^IS slopes, and black bars illustrate the mean of the slope of the respective group (upper panel: mean of MR3 recurrence group = 0.017 and MR4 recurrence group = 0.014; lower panel: mean of MR3 nonrecurrence group = −0.005 and MR4 nonrecurrence group = 0.006). (B) Recurrence-free survival of patients with either negative/low (green) or high slope (red) during the 12-month reduction period (n = 171). The patients with high slopes are further separated as to whether they present with disease recurrence during the half dose period (light red) or after treatment stop.